Table 1.
Baseline characteristics of prostate cancer cases and controls
| Cases in genotype analyses (N=982) | Cases in plasma analyses (N=602) | Controls (N=1,142) | |
|---|---|---|---|
| Mean age at baseline (±SD) | 59.2 (8.3) | 59.2 (8.2) | 59.7 (7.8) |
| Mean age at diagnosis (±SD) | 69.4 (7.3) | 68.6 (7.2) | - |
| BMI at baseline (%) | |||
| Normal (<25 kg/m2) | 573 (58.3) | 353 (58.6) | 696 (61.0) |
| Overweight (25–<30 kg/m2) | 376 (38.3) | 230 (38.2) | 411 (36.0) |
| Obese (≥30 kg/m2) | 33 (3.4) | 19 (3.2) | 35 (3.0) |
| Gleason score at diagnosis (%)* | |||
| 2–6 or well differentiated | 554 (61.4) | 351 (63.2) | - |
| 7 | 208 (23.1) | 125 (22.5) | - |
| 8–10 or poorly differentiated | 140 (15.5) | 79 (14.2) | - |
| Tumor stage at diagnosis (%)† | |||
| T1/T2 | 545 (72.0) | 351 (72.4) | - |
| T3/T4/N1/M1 | 212 (28.0) | 134 (27.6) | - |
| Date of diagnosis | |||
| Prior to 1992 | 387 (39.4) | 269 (44.7) | - |
| During/after 1992 | 595 (60.6) | 333 (55.3) | - |
*
Data on Gleason grade missing for 8% of cases in genotype and plasma analyses
†
Data on tumor stage missing for 23% of cases in genotype analyses and 19% in plasma analyses